CONTINUUS Pharmaceuticals’ vision for pharmaceutical manufacturing is that the entire process be integrated into a single end-to-end production line. This was achieved at a pilot scale at the Novartis-MIT Center for Continuous Manufacturing in 2011, as both upstream and downstream components were integrated into a seamless process that was completely automated and run under closed-loop control. This pilot plant was able to demonstrate significant operational advantages over the current batch standard (lead time reduction >90%, plant footprint reduction ~90%, improved quality assurance, and decreased environmental impact). In addition, we project that our Integrated Continuous Manufacturing (ICM) plant will be able to reduce COGS by >30-50%. In addition to these operational advantages, ICM will be able to provide benefits throughout the supply chain (Figure 1).
Figure 1. CONTINUUS Pharmaceuticals Offers Significant Advantages Throughout the Supply Chain
To implement ICM lines for our clients, we offer a phased approach whereby their investments can be de-risked. In this way, smaller investments early on will provide compelling results to justify the build-out of a commercial ICM plant. Furthermore, these ICM plants will be able to be located at our facilities or our clients’ facilities; they can be owned by us or our clients; and, they can be operated by our personnel or theirs. Please contact us to see how we can tailor an ICM product that suits your needs.